Right Science, Right Team, Right Timing
Commercializing a Breakthrough Epilepsy Drug, Aiming for Fast-Track Approval, and New Neurological Treatments
Multi-Indication Potential
Right Science. Right Team. Right Timing.
- Five targeted indications
- Epilepsy, Depression, PTSD, anxiety, TBI
- Designated pathway to orphan drug status for epilepsy
- Well-defined IP strategy and platform formulation
- Scalable platform across CNS disorders
“After examining CanaQuest's portfolio, I recognize the opportunity for CQ-001 to build on the successes of previously approved cannabidiol-based medications. With its combination of active compounds, preliminary data suggests that CQ-001 may offer enhanced benefits by targeting multiple mechanisms of action beyond those of cannabidiol alone.”
Jordyn Stuart, PhD
CanaQuest Acting Chief Scientific Officer
PTSD: post-traumatic stress disorder; TBI: traumatic brain injury, IP: intellectual property; CNS: central nervous system